title: [Novel drugs for COPD treatment].
abstract: Currently, numerous new compounds and inhaler types are reaching the market for the treatment of chronic obstructive pulmonary disease (COPD). They comprise new long-acting beta-2 agonists, muscarinic antagonists and inhaled corticosteroids. Most of them are for combination treatment in new fixed-dose inhalers. Even the combination of three components in one inhaler is under development. Thus, management of COPD are getting more differentiated but also much more complex. This review gives an overview of the state of art of pharmaceutical research in this area and offers a glimpse into the proximate future.
authors.affiliation: Klinik für Lungen- und Bronchialmedizin, Klinikum Kassel.
authors.forename: A
authors.initials: A
authors.lastname: Gillissen
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D058672:Adrenergic beta-2 Receptor Antagonists / Q000008:administration & dosage*; D015195:Drug Design; D019317:Evidence-Based Medicine; D006801:Humans; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000188:drug therapy*; D019141:Respiratory System Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D058672:Adrenergic beta-2 Receptor Antagonists; D018727:Muscarinic Antagonists; D019141:Respiratory System Agents